eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc. (EFTR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · EFTR · as of Sep 30, 2024
Ownership Breakdown
3
Institutional Holders
▼ 15 vs Q2
$4,330
Total Inst. Value
▼ $246,815 vs Q2
4.70M
Shares Outstanding
freeFloat 99.19%
114,201
13F Shares Held
▼ 753,237 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
EFTR largest shareholders · institutional ownership
Q3 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SABBY MANAGEMENT, LLC pharmaceutical preparations | 61.8K | 1.51% | 1.51% | $2.29M | Nov 14, 2024 | ▼ 290.3K |
BLACKSTONE INC. pharmaceutical preparations | 52.3K | 1.28% | 1.28% | $2.04M | Nov 14, 2024 | — held |
BARCLAYS PLC pharmaceutical preparations | 100 | 0.25% | 0.25% | $4,000 | Mar 31, 2026 | — held |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2024 | EXIT |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 12, 2024 | EXIT |
ALYESKA INVESTMENT GROUP, L.P. pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2024 | EXIT |
HRT FINANCIAL LP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 12, 2024 | EXIT |
CARLYLE GROUP INC. pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 8, 2024 | EXIT |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2024 | EXIT |
VIRTU FINANCIAL LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 20, 2024 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2024 vs prior quarter
Q3 2024
0
Increased
+0 shares0
New Positions
first time holders1
Decreased
−290.3K shares15
Sold Out
fully exitedNet shares change (top 50)
290.3K
+0 / −290.3K
Net new holders
-16
0 new / 15 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
EFTR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
8
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Loewy Caroline M director | Jun 13, 2024 | Award | 800 | $1.38 | $1.1K | 800 | Form 4 ↗ |
Klencke Barbara director | Jun 13, 2024 | Award | 800 | $1.38 | $1.1K | 800 | Form 4 ↗ |
Ehrlich Christopher B director | Jun 13, 2024 | Award | 800 | $1.38 | $1.1K | 800 | Form 4 ↗ |
Harrington-Smith Kristen director | Jun 13, 2024 | Award | 800 | $1.38 | $1.1K | 800 | Form 4 ↗ |
Gallagher Brian M. Jr. director | Jun 13, 2024 | Award | 800 | $1.38 | $1.1K | 800 | Form 4 ↗ |
Bhatt Elizabeth director | Jun 13, 2024 | Award | 800 | $1.38 | $1.1K | 800 | Form 4 ↗ |
Byrnes Michael Chief Financial Officer | May 15, 2024 | Award | 1,387 | $1.68 | $2.3K | 3.1K | Form 4 ↗ |
WORLAND STEPHEN T Chief Executive Officer | May 15, 2024 | Award | 1,806 | $1.68 | $3.0K | 12.5K | Form 4 ↗ |
Loewy Caroline M director | Feb 19, 2024 | Award | 2,000 | $11.32 | $22.6K | 2.0K | Form 4 ↗ |
Bhatt Elizabeth director | Feb 19, 2024 | Award | 2,000 | $11.32 | $22.6K | 2.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
eFFECTOR Therapeutics, Inc. (EFTR) is primarily owned by institutional investors, who hold approximately 2.4% of total shares outstanding. Company insiders own approximately 0.81%, while retail and public investors account for the remaining 96.76%.
The largest institutional shareholder of eFFECTOR Therapeutics, Inc. is SABBY MANAGEMENT, LLC, holding approximately 61,758 shares — equal to 1.51% of outstanding shares — as of September 30, 2024.
A total of 3 institutional investors currently hold EFTR stock, with a combined institutional value of approximately $4,330 as of the most recent 13F filing period.
Frequently asked questions
EFTR ownershipeFFECTOR Therapeutics, Inc. (EFTR) is primarily owned by institutional investors, who hold approximately 2.4% of shares. The largest shareholder is SABBY MANAGEMENT, LLC with a 1.51% stake. Company insiders hold 0.81%. Data sourced from SEC Form 13F as of September 30, 2024.